ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE) — Devanand Sarkar (VIRGINIA COMMONWEALTH UNIVERSITY)
OVERALL: SUMMARY Hepatocellular carcinoma (HCC), the primary malignancy of hepatocytes, is a diagnosis with bleak outcomes. With the alarming rise in global obesity incidence, obesity-induced non-alco
| Project title | ExpLoiting thErapeutic VulnerAbilities in hepaTocEllular carcinoma (ELEVATE) |
|---|---|
| Project number | 1P01CA275740-01A1 |
| PI name | Devanand Sarkar |
| Institution | VIRGINIA COMMONWEALTH UNIVERSITY |
| Funding mechanism | P01 |
| Agency | NCI |
| Award amount | $2.68M |
| Fiscal year | 2024 |
| Project start | 2024-08-08T00:00:00 |
| Project end | 2029-07-31T00:00:00 |
| Abstract | OVERALL: SUMMARY Hepatocellular carcinoma (HCC), the primary malignancy of hepatocytes, is a diagnosis with bleak outcomes. With the alarming rise in global obesity incidence, obesity-induced non-alco |
| Key terms | <Anti-VEGF><Anti-VEGF Humanized Monoclonal Antibody><Anti-VEGF RhuMAb><Antibodies><Avian Myelocytoma |
$799/mo
Try GrantRadar →